0.691

1.62% +0.011

After Hours: .691

DBV Technologies ADR (DBVT)

Overview News Price History Option Chain Discussions Forecast

DBV Technologies ADR stock is currently priced at $0.691, with a 24-hour trading volume of 2,576. It has seen a +1.62% increased in the last 24 hours and a -13.21% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $0.685 pivot point. If it approaches the $0.7098 resistance level, significant changes may occur.

Previous Close:

$0.68

Open:

$0.7142

24h Volume:

2,576

Market Cap:

$132.91M

Revenue:

Net Income/Loss:

$-72.73M

P/E Ratio:

-1.245

EPS:

-0.555

Net Cash Flow:

$-80.33M

1W Performance:

+1.62%

1M Performance:

-13.21%

6M Performance:

-37.75%

1Y Performance:

-56.54%

1D Range:

$0.665

$0.7142

52W Range:

$0.65

$2.37

DBV Technologies ADR Stock (DBVT) Company Profile

Name

DBV Technologies ADR

Sector

Healthcare (1198)

Industry

Biotechnology (688)

Phone

33 1 55 42 78 78

Address

177-181 avenue Pierre Brossolette, Montrouge

Employee

244

Twitter

@dbvtechnologies

Next Earnings Date

Latest SEC Filings

DBVT's Discussions on Twitter

DBV Technologies ADR Stock (DBVT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-04-23	Upgrade	Societe Generale	Hold → Buy
Dec-16-22	Downgrade	Goldman	Neutral → Sell
May-10-22	Downgrade	Goldman	Buy → Neutral
Sep-14-21	Upgrade	Societe Generale	Hold → Buy
Jan-22-21	Downgrade	Societe Generale	Hold → Sell
Nov-02-20	Upgrade	Societe Generale	Sell → Hold
Aug-06-20	Downgrade	Societe Generale	Buy → Sell
Aug-05-20	Reiterated	H.C. Wainwright	Buy
Mar-17-20	Downgrade	Stifel	Buy → Hold
Jan-09-20	Upgrade	Stifel	Hold → Buy
Dec-16-19	Initiated	Citigroup	Buy
Sep-05-19	Resumed	Morgan Stanley	Equal-Weight
Jun-17-19	Initiated	Goldman	Buy
Dec-20-18	Downgrade	Barclays	Overweight → Equal Weight
Dec-20-18	Downgrade	BofA/Merrill	Buy → Underperform
Dec-20-18	Downgrade	Jefferies	Buy → Hold
Dec-20-18	Downgrade	Stifel	Buy → Hold
Oct-31-17	Upgrade	Societe Generale	Sell → Hold
Oct-24-17	Downgrade	Societe Generale	Buy → Sell
Oct-23-17	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Jun-23-17	Initiated	Deutsche Bank	Buy
Mar-16-17	Upgrade	Societe Generale	Hold → Buy
Sep-26-16	Initiated	JMP Securities	Mkt Outperform
Dec-03-15	Initiated	Barclays	Overweight
Oct-23-15	Initiated	BofA/Merrill	Buy

View All

DBV Technologies ADR Stock (DBVT) Latest News

Information regarding the total number of voting rights and total number of shares of the Company as of March 31, 2024

GlobeNewswire Inc.

DBV Technologies announces filing of 2023 Annual Report on Form 10-K and Universal Registration Document

GlobeNewswire Inc.

DBV Technologies Reports Full Year 2023 Financial Results and Business Update

GlobeNewswire Inc.

DBV Technologies to Report Full Year 2023 Financial Results and Business Update on March 7, 2024

GlobeNewswire Inc.

DBV Technologies to Participate in Upcoming AAAAI 2024 Congress

GlobeNewswire Inc.

DBV Technologies And 2 Other Stocks Under $2 Insiders Are Buying

Benzinga

DBV Technologies ADR Stock (DBVT) Financials Data

DBV Technologies ADR (DBVT) Net Income 2024

DBVT net income (TTM) was -$72.73 million for the quarter ending December 31, 2023, a +24.46% increase year-over-year.

DBV Technologies ADR (DBVT) Cash Flow 2024

DBVT recorded a free cash flow (TTM) of -$80.33 million for the quarter ending December 31, 2023, a -42.38% decrease year-over-year.

DBV Technologies ADR (DBVT) Earnings per Share 2024

DBVT earnings per share (TTM) was -$0.38 for the quarter ending December 31, 2023, a +40.62% growth year-over-year.

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults. The company is also developing Viaskin Milk that is in Phase II clinical trial for the treatment of Immunoglobulin E mediated cow's milk protein allergy (CMPA) and milk-induced eosinophilic esophagitis; Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordatella pertussis. Its other earlier stage research programs include vaccine for respiratory syncytial virus, as well as treatments for Crohn's disease, hemophilia A, celiac disease, and type I diabetes. The company has collaboration with Nestlé Health Science to develop MAG1C, an atopy patch test for the diagnosis of CMPA in infants and toddlers. DBV Technologies S.A. was founded in 2002 and is headquartered in Montrouge, France.